P
Pottayil G. Sasikumar
Researcher at Lund University
Publications - 23
Citations - 617
Pottayil G. Sasikumar is an academic researcher from Lund University. The author has contributed to research in topics: Immune checkpoint & Immune system. The author has an hindex of 8, co-authored 23 publications receiving 474 citations.
Papers
More filters
Patent
Immunosuppression modulating compounds
Pottayil G. Sasikumar,Murali Ramachandra,Suresh Kumar Vadlamani,Koteswara Rao Vemula,Leena Khare Satyam,Krishnaprasad Subbarao,Rajeev K. Shrimali,Sreenivas Kandepu +7 more
TL;DR: The peptide based compositions for treatment of cancer or treatment of infections via immunopotentiation caused by inhibition of immunosuppressive signaling induced by programmed cell death 1 (PD1) signalling pathway were presented in this paper.
Journal ArticleDOI
Anti-PD-L1 peptide improves survival in sepsis.
Yuichiro Shindo,Jacquelyn S. McDonough,Katherine Chang,Murali Ramachandra,Pottayil G. Sasikumar,Richard S. Hotchkiss +5 more
TL;DR: Compound 8 significantly improved survival in a clinically relevant immunosuppressive model of sepsis and support immunoadjuvant therapy targeting T-cell exhaustion in this lethal disease.
Journal ArticleDOI
Small-Molecule Immune Checkpoint Inhibitors Targeting PD-1/PD-L1 and Other Emerging Checkpoint Pathways.
TL;DR: Small-molecule inhibitors simultaneously targeting two non-redundant checkpoint inhibitor pathways as an approach to improve the response rate are described.
Journal ArticleDOI
PD-1 derived CA-170 is an oral immune checkpoint inhibitor that exhibits preclinical anti-tumor efficacy.
Pottayil G. Sasikumar,Naremaddepalli S. Sudarshan,Sreenivas Adurthi,Raghuveer Ramachandra,Dodderi S. Samiulla,Anirudha Lakshminarasimhan,Anuradha Ramanathan,Talapaneni Chandrasekhar,Amit A. Dhudashiya,Sumalatha Rani Talapati,Nagesh Gowda,Sreenivasulareddy Palakolanu,Jiju Mani,Bandi Srinivasrao,David Joseph,Nigam Kumar,Rashmi Nair,Hanudatta S. Atreya,Nagaraj Gowda,Murali Ramachandra +19 more
TL;DR: CA-170 as mentioned in this paper is an amino acid inspired small molecule inhibitor of PD-L1 and VISTA derived from the interface of the PD-1 and PD-l1.
Journal ArticleDOI
A Rationally Designed Peptide Antagonist of the PD-1 Signaling Pathway as an Immunomodulatory Agent for Cancer Therapy.
Pottayil G. Sasikumar,Raghuveer Ramachandra,Sreenivas Adurthi,Amit A. Dhudashiya,Sureshkumar Vadlamani,Koteswararao Vemula,Sriharibabu Vunnum,Leena Khare Satyam,Dodderi S. Samiulla,Krishnaprasad Subbarao,Rashmi Nair,Rajeev K. Shrimali,Nagaraj Gowda,Murali Ramachandra +13 more
TL;DR: NP-12 is the first rationally designed peptide therapeutic targeting PD-1 signaling pathways exhibiting immune activation, excellent antitumor activity, and potential for better management of irAEs.